1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Neurocrine’s Crinecerfont Draws Cautious Optimism On Clinical Meaningfulness

 
• By Alaric DeArment

The biotech plans to file for approval for congenital adrenal hyperplasia (CAH) next year and is now looking ahead to a pediatric study, which may pose lower risk.

• Source: Shutterstock

Some questions remain around the clinical meaningfulness as well as the commercial opportunity based on Neurocrine Biosciences, Inc.’s Phase III CAHtalyst trial of crinecerfont in adults with classic congenital adrenal hyperplasia, but analysts expressed confidence given the study’s overall success and high degree of statistical significance.

The biotech company announced topline results on 12 September, saying that CAHtalyst met the primary endpoint, showing a statistically significant reduction in daily glucocorticoid use at week 24 compared with...

Key Takeaways

  • Neurocrine’s Phase III CAHtalyst trial of crinecerfont in congenital adrenal hyperplasia met its primary and key secondary endpoints.

  • Numerical data for the primary endpoint...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

More from R&D

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.